European Penny Stocks To Watch In June 2025

Simply Wall St

The European markets have recently faced challenges, with the pan-European STOXX Europe 600 Index declining by 1.54%, largely due to concerns about escalating tensions in the Middle East. Amidst this backdrop, investors are increasingly turning their attention to penny stocks, which despite their somewhat outdated moniker, continue to offer intriguing opportunities for growth and value. These stocks typically represent smaller or newer companies that can deliver potential upside when backed by strong financials and solid fundamentals.

Top 10 Penny Stocks In Europe

NameShare PriceMarket CapRewards & Risks
Mistral Iberia Real Estate SOCIMI (BME:YMIB)€1.03€19.6M✅ 2 ⚠️ 4 View Analysis >
KebNi (OM:KEBNI B)SEK1.90SEK515.19M✅ 3 ⚠️ 4 View Analysis >
Angler Gaming (NGM:ANGL)SEK3.74SEK280.44M✅ 4 ⚠️ 2 View Analysis >
Cellularline (BIT:CELL)€2.85€60.11M✅ 4 ⚠️ 2 View Analysis >
Fondia Oyj (HLSE:FONDIA)€4.46€16.68M✅ 2 ⚠️ 3 View Analysis >
Libertas 7 (BME:LIB)€1.91€40.7M✅ 3 ⚠️ 4 View Analysis >
Bredband2 i Skandinavien (OM:BRE2)SEK2.38SEK2.28B✅ 4 ⚠️ 1 View Analysis >
Hifab Group (OM:HIFA B)SEK3.52SEK214.15M✅ 2 ⚠️ 2 View Analysis >
Deceuninck (ENXTBR:DECB)€2.11€291.32M✅ 3 ⚠️ 1 View Analysis >
Netgem (ENXTPA:ALNTG)€0.962€32.44M✅ 3 ⚠️ 2 View Analysis >

Click here to see the full list of 327 stocks from our European Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Cellectis (ENXTPA:ALCLS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cellectis S.A. is a clinical-stage biotechnological company focused on developing gene-editing products, including allogeneic chimeric antigen receptor T-cells for immuno-oncology and gene therapy candidates for various therapeutic areas, with a market cap of €92.68 million.

Operations: Cellectis generates revenue primarily from its therapeutics segment, amounting to $54.75 million.

Market Cap: €92.68M

Cellectis S.A., with a market cap of €92.68 million, is navigating the volatile landscape of penny stocks in Europe. Despite being unprofitable, the company has managed to reduce its losses over the past five years and maintains a cash runway exceeding three years due to positive free cash flow. Recent earnings showed revenue growth to US$12.03 million for Q1 2025 but also reported a net loss of US$18.13 million. The company's innovative gene-editing techniques presented at various conferences highlight its potential in advancing next-generation therapies, though profitability remains elusive in the near term.

ENXTPA:ALCLS Financial Position Analysis as at Jun 2025

Impact Coatings (OM:IMPC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Impact Coatings AB (publ) offers physical vapor deposition (PVD) surface treatment solutions for hydrogen and metallization applications across Sweden, Europe, North America, Asia, and other international markets, with a market cap of SEK287.83 million.

Operations: The company's revenue is derived from its Specialty Chemicals segment, totaling SEK127.6 million.

Market Cap: SEK287.83M

Impact Coatings AB, with a market cap of SEK287.83 million, is navigating the penny stock space with its PVD surface treatment solutions. The company reported Q1 2025 revenue of SEK19.7 million, marking significant growth from the previous year, yet remains unprofitable with a net loss of SEK14.2 million. Despite having no debt and short-term assets exceeding liabilities, Impact Coatings faces financial challenges with less than a year of cash runway if current cash flow trends continue. Recent strategic collaborations aim to leverage its technology in hydrogen applications, potentially enhancing future revenue streams and market presence.

OM:IMPC Financial Position Analysis as at Jun 2025

Exasol (XTRA:EXL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Exasol AG specializes in developing databases for analytics and data warehousing across multiple regions, including Germany, Austria, Switzerland, Great Britain, North America, and internationally, with a market cap of €78.69 million.

Operations: The company's revenue is segmented as follows: €2.31 million from Great Britain, €7.62 million from North America, €25.97 million from the DACH region (Germany, Austria, Switzerland), and €3.73 million from the Rest of Europe and Rest of World combined.

Market Cap: €78.69M

Exasol AG, with a market cap of €78.69 million, has recently become profitable, distinguishing itself in the penny stock landscape. The company's revenue is primarily driven by the DACH region at €25.97 million, followed by North America and Great Britain. Exasol's financial health is strong with no debt and short-term assets exceeding both short-term and long-term liabilities. Despite high share price volatility, it trades significantly below its estimated fair value. The board's inexperience may pose governance challenges; however, management stability offers some reassurance as earnings are forecast to grow 34.36% annually amidst confirmed revenue growth guidance for 2025.

XTRA:EXL Financial Position Analysis as at Jun 2025

Seize The Opportunity

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Impact Coatings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com